GlassScriptPhysician profile
Tikku George
NPI 1619532033
$6,756.06
in general payments reported to CMS, 2019-2025
36 companies · $4,719 in 2025
The $4,719 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $40.13 · 2021: $402 · 2022: $222 · 2023: $350 · 2024: $1,022 · 2025: $4,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,694 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200 · Consulting Fee: $150 · Education: $46.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,694.36 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
| Consulting Fee | $150.00 |
| Education | $46.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $968.86 | 2023-2025 | Rystiggo, Zilbrysq, Fintepla |
| Abbvie INC. | $678.96 | 2024-2025 | |
| Pfizer INC. | $457.66 | 2024-2025 | |
| Biogen, INC. | $443.61 | 2022-2025 | Tysabri, Vumerity, Leqembi |
| Eisai INC. | $410.88 | 2020-2025 | |
| Jazz Pharmaceuticals INC. | $393.96 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $345.38 | 2023-2025 | Ingrezza |
| Amgen INC. | $268.98 | 2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $264.25 | 2021-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $245.83 | 2024-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Celgene Corporation | $217.23 | 2025 | Zeposia |
| Neurelis, INC. | $204.07 | 2024-2025 | Valtoco |
| Argenx US, INC. | $147.66 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Novartis Pharmaceuticals Corporation | $139.14 | 2024-2025 | |
| Lilly USA, LLC | $133.08 | 2024-2025 | Kisunla, Emgality |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immedica Pharma US, INC. | $124.95 | 2023 | |
| Aucta Pharmaceuticals, INC. | $122.24 | 2025 | Motpoly Xr |
| Sk Life Science, INC. | $120.75 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $109.95 | 2021 | |
| Janssen Biotech, INC. | $109.70 | 2025 | |
| Lundbeck LLC | $105.86 | 2024-2025 | Vyepti |
| Acadia Pharmaceuticals INC | $101.66 | 2025 | Nuplazid |
| Azurity Pharmaceuticals, INC. | $99.60 | 2024-2025 | Horizant |
| E.R. Squibb & Sons, L.L.C. | $86.62 | 2025 | Zeposia |
| Alkermes, INC. | $82.33 | 2021 | |
| Tg Therapeutics, INC. | $66.43 | 2025 | |
| Genentech USA, INC. | $64.83 | 2024-2025 | Ocrevus Zunovo, Enspryng, Ocrevus |
| Abbott Laboratories | $41.41 | 2024-2025 | Infinity |
| Medtronic, INC. | $37.92 | 2023 | Sensight |
| Csl Behring | $36.20 | 2025 | Hizentra |
| Tanabe Pharma America, INC. | $32.49 | 2025 | Radicava |
| Ge Healthcare | $22.17 | 2025 | |
| C2n Diagnostics, LLC | $20.92 | 2025 | Precivityad2 |
| Microtransponder, INC. | $19.39 | 2025 | |
| Amneal Pharmaceuticals LLC | $16.60 | 2025 | Crexont |
| Tonix Medicines, INC. | $14.49 | 2025 | Zembrace Symtouch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tikku George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.